Innovation Pharmaceuticals Inc., of Beverly, Mass., said the last patient completed treatment in its phase IIb trial of Prurisol (abacavir acetate) for the treatment of psoriasis. Read More
Semma Therapeutics Inc., of Cambridge, Mass., a company focused on the development of regenerative medicines, has completed an oversubscribed $114 million series B financing. Proceeds will be used to bring its lead development program, encapsulated stem cell-derived islets, through clinical proof of concept in patients and to continue exploration of other regenerative medicine therapeutics, the company said. Read More
Soligenix Inc., of Princeton, N.J., said it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's New Jersey Technology Business Tax Certificate Transfer program. Read More
HONG KONG – AJ Biologics Sdn. Bhd., of Malaysia, recently broke ground on the first vaccine manufacturing facility in the country and is going after innovation in the vaccine space with the new plant. Read More
BOGOTA, Colombia – With an investment of more than $30 million in its new Bthek Biotecnologia development and production plant, Brazilian biopharma company União Química Farmacêutica Nacional SA is boosting its presence in the Latin American biotech market. Read More
PERTH, Australia – Melbourne-based Starpharma Ltd. submitted a rolling submission of its Vivagel new drug application (NDA) to the FDA for preventing and treating recurrent bacterial vaginosis (rBV). With that submission, the biotech company joins a very limited club of Australian biotechs to bring their products all the way through to registration. Read More
FDA Commissioner Scott Gottlieb discussed briefly the agency's draft guidance regarding communication of health care economic information at a Nov. 30 congressional hearing, and said the objective at the agency is to "go beyond the draft guidance to provide a framework" for sponsors' communication of such data to formularies and others. Read More
The National Academies of Sciences, Engineering and Medicine issued a report that offers eight recommendations with 27 actions for implementation, all aimed at improving the affordability of prescription drugs without discouraging innovation. Read More
